Johnson & Johnson's COVID-19 vaccine was 73.6 percent effective in preventing infection, according to a real-world study published Nov. 2 in JAMA Network Open.
The study analyzed patients from Rochester, Minn.-based Mayo Clinic from Feb. 27 to July 22. It involved 8,889 patients who received Johnson & Johnson's vaccine and 88,898 unvaccinated patients.
Sixty of the vaccinated patients tested positive for COVID-19, while 2,236 of the unvaccinated patients tested positive. Infection data was determined by PCR tests.
The researchers concluded that the vaccine led to a 3.73-fold reduction in infections.